Researchers at the University of Cambridge have developed an innovative method to improve the diagnosis of bipolar disorder by combining an online psychiatric evaluation with a blood test that identifies specific biomarkers. This dual approach aims to address the frequent misdiagnosis of bipolar disorder as major depressive disorder, which occurs in nearly 40% of cases, despite their differing treatment needs. The blood test alone can diagnose about 30% of bipolar disorder cases, but its accuracy notably increases when integrated with a digital health assessment.
Using data from the Delta study, which involved over 3,000 participants, the researchers collected extensive online assessments and dried blood samples to analyze metabolites linked to bipolar disorder. Their findings indicated a significant correlation between the identified biomarkers and manic symptoms. This combined approach has shown promise in expediting accurate diagnoses and potentially alleviating the strain on healthcare professionals.
The research not only enhances diagnostic capabilities but may also serve as a basis for discovering new treatment targets. As the study progresses, it presents exciting opportunities for further exploration into the biological underpinnings of mood disorders, with a patent already filed for the technology.
